ClinicalTrials.govpublic full text
An Open-label Phase II Study of Lorvotuzumab Mertansine
leukemia, hematological malignancy, myelofibrosis, mf, blastic plasmacytoid dendritic cell neoplasm, bpdcn, cd56 tumor marker, acute myeloid leukemia, aml, natural-killer leukemia, acute lymphoblastic leukemia, all
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 879723
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.